Department of Thoracic, Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
J Med Invest. 2020;67(3.4):298-303. doi: 10.2152/jmi.67.298.
Introduction : Central venous catheter (CVC) use is essential for treating esophageal cancer. Peripherally inserted central catheters (PICC) are commonly used recently for improved patient comfort and safety. We compared centrally inserted central catheters (CICC) and PICC insertions and examined their safety. Methods : We retrospectively investigated complications at the catheter insertion and post-insertion for 199 patients' esophageal cancer treatment (CICC : 45, PICC : 154) from 2013 to 2018. In addition, we summarized the results of catheter tip culture. Results : No serious complications occurred at the catheter insertion in either group. The rate of complications at catheter insertion was 5.8% for PICC and 6.7% for CICC patients. Post-insertion complications were observed in 6.5% and 11.1% of patients with PICC and CICC, respectively, and this difference was not significant. The incidence of catheter-related blood stream infection (CRBSI) was significantly lower in PICC than CICC patients (0.3 vs. 1.8 / 1,000 catheter-days ; p = 0.029). Catheter-related thrombosis was observed in PICC : 0.5 and CICC : 0.6, and occlusion due to blood flow reversal was observed in PICC : 0.5 and CICC : 0.6. Conclusion : PICCs are safer and more effective than CICCs for the treatment of esophageal cancer, and reduce the incidence of CRBSI. We hope to standardize the insertion procedures, conventionalize techniques, and establish training systems. J. Med. Invest. 67 : 298-303, August, 2020.
中央静脉导管(CVC)的使用对治疗食管癌至关重要。最近,外周静脉置入中心静脉导管(PICC)因其提高了患者的舒适度和安全性而被广泛应用。我们比较了中心静脉导管(CICC)和 PICC 的插入,并检查了它们的安全性。方法:我们回顾性调查了 199 例食管癌患者(CICC:45 例,PICC:154 例)从 2013 年到 2018 年的导管插入和置管后的并发症。此外,我们总结了导管尖端培养的结果。结果:两组患者在导管插入时均未发生严重并发症。PICC 组和 CICC 组的导管插入并发症发生率分别为 5.8%和 6.7%。PICC 组和 CICC 组分别有 6.5%和 11.1%的患者发生置管后并发症,差异无统计学意义。PICC 组的导管相关性血流感染(CRBSI)发生率明显低于 CICC 组(0.3 比 1.8/1000 导管日;P=0.029)。PICC 组和 CICC 组分别有 0.5%和 0.6%的患者出现导管相关性血栓形成,PICC 组和 CICC 组分别有 0.5%和 0.6%的患者出现因血流逆转导致的导管阻塞。结论:与 CICC 相比,PICC 治疗食管癌更安全、更有效,可降低 CRBSI 的发生率。我们希望能规范置管程序、常规化技术,并建立培训系统。J. Med. Invest. 67:298-303,2020 年 8 月。